Century Therapeutics, Inc. (IPSC) has a negative trailing P/E of -20.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -4.84%.
Criteria proven by this page:
Overall SharesGrow Score: 59/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -5.1 | 0.00 | -13.63 | 0.00 | - |
| 2020 | -23.4 | 0.30 | -11.76 | 0.00 | - |
| 2021 | -9.1 | -0.12 | 2.20 | 0.00 | - |
| 2022 | -2.3 | -0.07 | 0.98 | 56.99 | - |
| 2023 | -1.4 | -1.09 | 1.07 | 88.11 | - |
| 2024 | -0.6 | 0.02 | 0.49 | 12.06 | - |
| 2025 | -9.0 | 0.10 | 0.54 | 0.79 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-4.49 | $0.00 | $-245.98M | - |
| 2020 | $-1.00 | $0.00 | $-54.66M | - |
| 2021 | $-1.74 | $0.00 | $-95.82M | - |
| 2022 | $-2.27 | $5.2M | $-130.93M | -2518.4% |
| 2023 | $-2.30 | $2.24M | $-136.67M | -6115.1% |
| 2024 | $-1.61 | $6.59M | $-126.57M | -1920.9% |
| 2025 | $-0.11 | $109.16M | $-9.58M | -8.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.54 | $-0.60 – $-0.47 | $4.72M | $4.72M – $4.72M | 2 |
| 2027 | $-0.47 | $-0.59 – $-0.35 | $3.74M | $3.74M – $3.74M | 2 |
| 2028 | $-0.43 | $-0.50 – $-0.36 | $1.18M | $1.18M – $1.18M | 2 |
| 2029 | $-0.50 | $-0.50 – $-0.50 | $375K | $375K – $375K | 1 |
| 2030 | $-0.39 | $-0.39 – $-0.39 | $77.6M | $77.6M – $77.6M | 1 |
